Eric J Sherman
Overview
Explore the profile of Eric J Sherman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
2831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hung T, Kuperman G, Sherman E, Ho A, Weng C, Pfister D, et al.
J Med Internet Res
. 2024 Oct;
26:e60695.
PMID: 39405514
No abstract available.
2.
Desilets A, Vos J, Katabi N, Kuo F, Nadeem Z, Linxweiler M, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5281-5292.
PMID: 39352719
Purpose: There is a significant need for effective therapies to treat recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC). This study evaluated the multitargeted VEGFR tyrosine kinase inhibitor (TKI) regorafenib in patients...
3.
Gui C, Wray R, Schoder H, Deasy J, Grkovski M, Humm J, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2436407.
PMID: 39348119
Importance: Given high rates of locoregional control after definitive management of head and neck squamous cell carcinoma (HNSCC), better methods are needed to project distant metastasis (DM) risk. Tumor hypoxia...
4.
Konda B, Sherman E, Massarelli E, Nieva J, Muzaffar J, Morris 3rd J, et al.
J Clin Endocrinol Metab
. 2024 Aug;
110(3):830-837.
PMID: 39133806
Background: This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer....
5.
French J, Haugen B, Worden F, Bowles D, Gianoukakis A, Konda B, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3757-3767.
PMID: 38922338
Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the...
6.
Desilets A, Pfister D, Stein S, Wong W, Sherman E, Fetten J, et al.
Oral Oncol
. 2024 May;
154:106861.
PMID: 38795600
Objectives: Epidermal growth factor receptor (EGFR) inhibition with cetuximab is a standard treatment for head and neck squamous cell carcinoma (HNSCC). Activation of the receptor tyrosine kinases AXL, MET and...
7.
Janopaul-Naylor J, Boe L, Yu Y, Sherman E, Pfister D, Lee N, et al.
Head Neck
. 2024 May;
46(9):2292-2300.
PMID: 38794815
Background: Prior work documented circadian rhythm impacts on efficacy and toxicity of cancer therapies. Methods: Secondary analysis of prospective, phase II trial of metastatic HNSCC randomized to nivolumab+/-SBRT. Used cutoffs...
8.
Lee N, Sherman E, Riaz N
J Clin Oncol
. 2024 May;
42(23):2836-2837.
PMID: 38788165
No abstract available.
9.
Youssef I, Mohamed N, Kallini D, Zakeri K, Lin H, Han D, et al.
Int J Radiat Oncol Biol Phys
. 2024 Mar;
120(5):1326-1331.
PMID: 38499254
Purpose: One main advantage of proton therapy versus photon therapy is its precise radiation delivery to targets without exit dose, resulting in lower dose to surrounding healthy tissues. This is...
10.
Lee N, Sherman E, Schoder H, Wray R, Boyle J, Singh B, et al.
J Clin Oncol
. 2024 Jan;
42(8):940-950.
PMID: 38241600
Purpose: Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)-related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could identify...